Home » Free Resources » Core Industry Metrics

Core Industry Metrics

As part of our mission to be the industry’s go-to source for market data, we provide and update this repository of core pharmaceutical industry metrics free to interested parties. To download the raw data MS Excel sets, use the links below.

CRO Core Metrics | CMO Core Metrics | Other Core Industry Metrics

Excel sets last updated: July 2022 with data from Q1, 2022

*IQVIA (Quintiles) total gross revenue has been adjusted to the proportion related to R&D solutions. =0.647
PRA and ICON merged in July, 2021 – data will be combined going forward (Q3, 2021)

*Celltrion removed because financials include innovator drugs and CDMO services.

*Companies included: Viatris, Teva, Sun Pharmaceutical, Aurobindo, Lupin
**Innovator companies and companies with medical device offerings omitted from above rankings.

*Companies included: J&J, Pfizer, Roche, Novartis, Merck & Co., GlaxoSmithKline, Sanofi, AbbVie, Takeda, Shanghai Pharmaceuticals

Top 20 Drug Sales

Source: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales

No.

Drug Name

Active Ingredient

Approval Date

FDA-approved use on approval date*

Quviviq

daridorexant

1/7/22

To treat insomnia

Cibinqo

abrocitinib

1/14/22

To treat refractory, moderate-to-severe atopic dermatitis

Kimmtrak

tebentafusp-tebn

1/25/22

To treat unresectable or metastatic uveal melanoma

Vabysmo

faricimab-svoa

1/28/22

To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema

Enjaymo

sutimlimab-jome

2/4/22

To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease

Pyrukynd

mitapivat

2/17/22

To treat hemolytic anemia in pyruvate kinase deficiency

Vonjo

pacritinib

2/28/22

To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets

Ztalmy

ganaxolone

3/18/22

To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder

Opdualag

nivolumab and relatlimab-rmbw

3/18/22

To treat unresectable or metastatic melanoma

Pluvicto

lutetium (177Lu) vipivotide tetraxetan

3/23/22

To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies

Vivjoa

oteseconazole

4/26/22

To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential

Voquezna

vonoprazan, amoxicillin, and clarithromycin

5/3/22

To treat Helicobacter pylori infection

Camzyos

mavacamten

4/28/22

To treat certain classes of obstructive hypertrophic cardiomyopathy

Vtama

tapinarof

5/23/22

To treat plaque psoriasis

Mounjaro

tirzepatide

5/13/22

To improve blood sugar control in diabetes, in addition to diet and exercise Press Release

Amvuttra

vutrisiran

6/13/22

To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

Core Industry Metrics

Core Industry Metrics Updates